Anzeige
Mehr »
Samstag, 16.08.2025 - Börsentäglich über 12.000 News
Neue Bohrergebnisse, Sichtgold und eine 7-fache Bewertungslücke, die zu groß ist, um sie zu ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
551 Leser
Artikel bewerten:
(2)

Esco Medical Selects Fairtility's CHLOE EQ as AI Decision Support Tool for MIRI® Time-Lapse Incubators

Strategic Collaboration Deal Powers MIRI® Time-Lapse Incubators with CHLOE EQ's Explainable AI, Improving Standard of Care Over Non-TLI Workflows

TEL AVIV, Israel, May 15, 2023 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, today announced that Esco Medical has selected CHLOE EQ as the AI decision support tool to integrate with its MIRI® Time-Lapse Incubators (TLI). CHLOE EQ will provide its transparent AI embryo quality assessment capabilities, enabling explainable AI output to recommend embryos most likely to lead to implantation in an IVF cycle.

The commercial collaboration will provide a joint offering of the MIRI® TLI with CHLOE EQ integrated with the MIRI server. CHLOE EQ captures and processes millions of data points per embryo and automatically inputs embryo annotations that are logged into the electronic medical record (EMR). CHLOE EQ utilizes this data to provide an embryo quality score, coupled with the biological data and insights to explain the system's data output. CHLOE EQ's automated capabilities provide embryologists with previously unachievable data to support consistent and standardized embryo selection decision support.

"After a rigorous assessment of the available AI support solutions to improve IVF outcomes, it was clear that Fairtility provided the most comprehensive offering," said Dr. Sanjay Bhojwani, Director and Global Head, Sales and Marketing, of Esco Medical. "The transparency of CHLOE EQ's analysis maximizes the impact of our time-lapse embryo image capture with AI-driven insights supported by clear biological data. We believe the combination of these two technologies will improve the standard of care through automation and increased transparency for both IVF professionals and patients."

CHLOE EQ 's transparent AI allows embryologists to reduce time spent on manual annotation by an average of 33 percent per cycle, resulting in up to a 50 percent increase of availability in fertility clinics. With an increased capacity for IVF cycles per embryologists, IVF clinics can make treatments available to more patients, while reducing embryologist burnout.

"Esco's MIRI® TLI empowered with CHLOE EQ can ease the workflow of embryologists, increase accuracy and streamline communication between IVF practitioners, clinic staff and prospective parents.", said Eran Eshed, CEO and Co-Founder of Fairtility. "The operational and clinical efficiency enabled by our complementary technologies is a step forward in meeting the growing demand of family building needs."

Esco Medical, a leading manufacturer of high-quality Assistive Reproductive Technology (ART), selected CHLOE EQ to augment the capabilities of its multi-room time-lapse incubator, MIRI® with transparent AI-derived embryo quality assessments. The choice to implement CHLOE EQ exclusively is a result of conclusive evidence-based research in the quality and reliability of Fairtility's technology.

About Fairtility
Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes. Equipping clinicians and their patients with unparalleled visibility into IVF treatment, CHLOE (Cultivating Human Life through Optimal Embryos) is the first and only transparent AI-based decision support tool that provides clinicians with the biological data supporting its AI-derived output. Beginning with CHLOE EQ, a proprietary embryo quality assessment platform, Fairtility is on a path to expand CHLOE's application to span the full IVF journey - from infertility cause assessment through transfer optimization. To learn more about Fairtility or schedule a demo, visit our website and follow us on Twitter and LinkedIn.

Media Contact
Nicole Kaufman-Grubner
+1-929-588-2011
Nicole.grubner@finnpartners.com

About Esco Medical

Esco Medical is a leading manufacturer and innovator of high-quality equipment such as long-term embryo incubators, ART workstations, Anti-Vibration Table, Time-Lapse incubators and is continuously developing advanced technologies to meet the increasing demand of the IVF industry. Most products are designed in Denmark and manufactured in the EU. Esco Medical is a business unit of the Esco Group, being a global life sciences tools provider in containment, clean air, pharmaceutical, and laboratory equipment technologies with active sales in over 100 countries and direct company offices in the top ten geographical markets. To learn more about Esco Medical, visit our website and follow us on Twitter and LinkedIn.

Cision View original content:https://www.prnewswire.co.uk/news-releases/esco-medical-selects-fairtilitys-chloe-eq-as-ai-decision-support-tool-for-miri-time-lapse-incubators-301824575.html

© 2023 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.